IL17A and colitis: In particular, treatment with two specific MALT1 inhibitors, MI-2 and mepazine, dose-dependently attenuated the symptoms of colitis in mice through a decrease in protein and mRNA levels of colonic TNF, IL-1β, IL-6, IL-18, IL-17A, and IFN-γ pro-inflammatory cytokines (66).